Keros Therapeutics, Inc.
KROS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001664710
In the last 90 days, Keros Therapeutics, Inc. insiders filed 1 open-market purchase and 4 sales; 132 institutions reported holding it in 13F filings for Q2 2026, worth $198.6M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $183.1M
- Insider buysLast 90 days, $10.3K in total
- 1
- Insider sellsLast 90 days, $101.1K in total
- 4
- 13F holdersQ2 2026, −16 vs. previous quarter
- 132
- 13F valueReported value at the end of Q2 2026
- $198.6M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $243.9M
- +6,769.4% year over year
- Net income, FY2025
- $87.0M
- No comparable prior period
- Free cash flow, FY2025
- $106.0M
- No comparable prior period
- Revenue, Q3 FY2026
- $40.0M
- +183.3% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 1.09M
- Shares sold short
- Change
- −50.6K
- −4.5% vs. previous
- Days to cover
- 7.06
- At average daily volume
Superinvestors holding KROS, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding KROS at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Keros Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 20, 2026 (view filing)4:10 PM ET | Aug 18 | 2 days | Tanini AnnitaCorp. Controller & VP, Finance | SSale | −1.22K | $10.29 | −$12.6K | −2.6%45.1K after | |
| Aug 20, 2026 (view filing)4:10 PM ET | Aug 18 | 2 days | Lerner Lorena RaquelChief Scientific Officer | SSale | −3.57K | $10.29 | −$36.7K | −11.5%27.6K after | |
| Aug 20, 2026 (view filing)4:10 PM ET | Aug 18 | 2 days | Cho EstherChief Legal Officer | SSale | −4.49K | $10.29 | −$46.2K | −11.1%35.8K after | |
| Aug 20, 2026 (view filing)4:10 PM ET | Aug 18 | 2 days | Newton Charles W.Director | SSale | −551 | $10.30 | −$5.68K | −4.4%12.1K after | 10b5-1 |
| Aug 19, 2026 (view filing)4:10 PM ET | Aug 17 | 2 days | Bienaime Jean JacquesDirector | PPurchase | +1.00K | $10.27 | +$10.3K | +5.4%19.6K after | 10b5-1 |
| Jul 17, 2026 (view filing)4:10 PM ET | Jul 15 | 2 days | Bienaime Jean JacquesDirector | PPurchase | +1.00K | $10.61 | +$10.6K | +5.7%18.6K after | 10b5-1 |
| Jun 17, 2026 (view filing) | Jun 15 | 2 days | Bienaime Jean JacquesDirector | PPurchase | +1.00K | $10.19 | +$10.2K | +6.0%17.6K after | 10b5-1 |
| Jun 15, 2026 (view filing) | Jun 11 | 4 days | Newton Charles W.Director | SSale | −550 | $10.04 | −$5.52K | −4.2%12.7K after | 10b5-1 |
| Jun 8, 2026 (view filing) | Jun 4 | 4 days | Knowles JuliusDirector | SSale | −2.63K | $10.73 | −$28.2K | −19.3%11.0K after | 10b5-1 |
| Jun 8, 2026 (view filing) | Jun 4 | 4 days | Farzan NimaDirector | SSale | −2.63K | $10.73 | −$28.2K | −21.2%9.77K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 132 holdersThe largest institutional positions in Keros Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 2,794,217 | $29.9M | 0.00% | +382,424+15.9% | Added |
| Nantahala Capital Management, LLC | 1,410,419 | $15.1M | 0.91% | +50,000+3.7% | Added |
| AQR Capital Management LLC | 967,859 | $10.4M | 0.00% | +561,296+138.1% | Added |
| Vanguard Capital Management LLC | 833,596 | $8.92M | 0.00% | +2,175+0.3% | Added |
| OrbiMed Advisors LLC | 759,155 | $8.12M | 0.15% | 00.0% | Unchanged |
| Federated Hermes, Inc. | 700,427 | $7.49M | 0.01% | +11,198+1.6% | Added |
| Vanguard Portfolio Management LLC | 652,635 | $6.98M | 0.00% | −29,408−4.3% | Reduced |
| Mackenzie Financial Corp | 628,438 | $6.72M | 0.01% | +475,988+312.2% | Added |
| Madison Avenue Partners, LP | 626,583 | $6.70M | 0.29% | 00.0% | Unchanged |
| Qube Research & Technologies Ltd | 608,837 | $6.51M | 0.01% | −116,089−16.0% | Reduced |
Holders of 5% or more of KROS
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Keros Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock Portfolio Management LLC | 13G/A | 9.10%1.81M shares | +3.40 ppfrom 5.70% | Jul 17, 20262 filings | Oct 27, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 8.40%1.67M shares | −1.70 ppfrom 10.10% | Apr 7, 20262 filings | Jul 29, 2026 | SEC |
| Nantahala Capital Management, LLC | 13G | 6.90%1.36M shares | New | May 15, 20261 filing | May 15, 2026 | SEC |